Podcasts about NPS

Astasia Myers, General Partner at Felicis, breaks down how venture capital is betting on AI and why over 80% of their recent investments are in this space. But this isn't just another “AI is the future” conversation. We dig into the real ROI happening right now in healthcare voice agents, why MIT says 95% of GenAI projects fail to reach production, and what needs to happen for that number to flip. If you're building, investing, or just trying to understand where enterprise AI is actually working (not just hyped), this episode cuts through the noise.What You'll LearnThe labor replacement opportunity: Why outcome-based AI solutions are targeting the $35 trillion labor market instead of just software budgets and how that changes everything for startups and investors.Voice AI's healthcare breakthrough: How voice agents are finally solving the operational bottlenecks in patient scheduling and communication, driving 24/7 availability with better NPS than human operators.Why 95% of GenAI projects still fail: The technical and infrastructure gaps that prevent most AI initiatives from making it to production and what's needed to fix that in 2026.The new technical risk era: After years of focusing purely on market risk, VCs are back to evaluating deep technical challenges in agentic systems, browser automation, and continuous learning loops.The exceptionalism filter: How early-stage investors are separating signal from noise when everyone can spin up an AI startup and why founder insights and lived experience matter more than ever.Timestamped Highlights00:31 – What Felicis invests in and the types of AI companies dominating their portfolio right now02:58 – Why healthcare tech is finally ready for its AI moment after years of long sales cycles and unclear ROI08:15 – How outcome-based pricing is changing the VC evaluation playbook and unlocking 10x larger TAMs13:26 – The mythical one-person billion-dollar company: Is it real, and how would investors even spot it?17:18 – Voice AI as the gateway for enterprise adoption and why this modality is different from Siri and Alexa20:08 – Democratizing AI: What ChatGPT did for consumers and what needs to happen for enterprise buildersOne Thing Worth Remembering“These technologies can price towards the labor replacement markets, which is about 10x the size of the software market itself. The ROI right now is so tangible that it is a time to invest.”Subscribe and Stay in the LoopIf this episode gave you a new angle on where AI is actually delivering value, share it with a founder or investor who needs to hear it. Subscribe so you don't miss the next conversation, and drop a comment if there's a topic or guest you want us to tackle next.

In this episode, Justin opens up about one of the biggest challenges nurse practitioners face when starting or growing a business, fear. Whether it's fear of failure, fear of losing stability, or fear of not being “ready,” these thoughts can stop even the most capable NPs from moving forward. Justin shares honest stories from his own journey, explains why fear is often just misplaced focus, and offers practical ways to push past anxiety and self-doubt. If you've ever felt stuck or afraid to take the next step, this conversation will help you shift your mindset and start taking real action toward your goals.

This week, Monika breaks down the sweeping changes in the National Pension System (NPS) that came into effect from October 1, 2025, and what they mean for investors planning their retirement. The revamped NPS now offers a more flexible and competitive alternative to mutual funds and insurance plans. Monika explains how, for years, the NPS remained a rigid, low-cost product built for simplicity — but one that often left investors frustrated with limited fund choices, compulsory annuity rules, and clunky access. The latest reforms mark a turning point, aiming to make NPS more adaptable and investor-friendly.Monika highlights the key updates that have transformed the product: investors can now allocate up to 100% in equities, choose multiple schemes within each asset class, and benefit from new fund options tailored to different risk profiles. With a modest increase in fund management costs and upcoming plans to relax the 40% annuity lock, the NPS may soon evolve into a strong, low-cost retirement vehicle. However, Monika cautions that while the direction of reform is promising, existing investors should evaluate the changes carefully and new investors might do well to wait until the new schemes show a track record.In listener questions, Sonal from Mumbai seeks advice on investing her retirement corpus to generate regular income, Mainak writes about evaluating his bank's “free” wealth management services and the hidden risks involved, and Aniket from Bengaluru asks how best to invest a small amount received as a gift for his newborn's future.Chapters:(00:00 – 00:00) The New NPS: What's Changed and Why It Matters(00:00 – 00:00) Should You Switch or Stay: Understanding the New Options(00:00 – 00:00) Investing Your Retirement Benefits Wisely(00:00 – 00:00) The Hidden Cost of “Free” Wealth Management(00:00 – 00:00) Building a Baby Fund the Smart WayIf you have financial questions that you'd like answers for, please email us at ⁠mailme@monikahalan.com⁠ Monika's book on basic money management⁠⁠https://www.monikahalan.com/lets-talk-money-english/⁠⁠Monika's book on mutual funds⁠https://www.monikahalan.com/lets-talk-mutual-funds/⁠Monika's workbook on recording your financial life⁠⁠https://www.monikahalan.com/lets-talk-legacy/⁠⁠Calculators⁠⁠https://investor.sebi.gov.in/calculators/index.html⁠⁠You can find Monika on her social media @monikahalan. Twitter ⁠⁠@MonikaHalan⁠⁠Instagram ⁠⁠@MonikaHalan⁠⁠Facebook ⁠⁠@MonikaHalan⁠⁠LinkedIn ⁠@MonikaHalan⁠Production House: ⁠www.inoutcreatives.com⁠Production Assistant:⁠ Anshika Gogoi⁠

On this accredited episode of NP Pulse: The Voice of the Nurse Practitioner, hear from experts Kathryn Evans-Kreider and Debbie Hinnen, who will be discussing the latest evidence and practical strategies for using continuous glucose monitoring (CGM) to improve outcomes, prevent complications and empower patients. NPs will learn how to apply current guidelines and expand CGM access across diverse patient populations. A participation code will be provided at the end of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center. Click on the "Next Steps" button of the activity and: Enter the participation code that was provided. Complete the posttest. Complete the activity evaluation. This will award your continuing education (CE) credit and certificate of completion. CE will be available through Oct. 31, 2026. Podcast Resource: ClinicalBrief_TacklingTherapeuticInertia.pdf This activity is supported by an independent medical educational grant from Abbott Diabetes.

In the news: an arrest is made in the case of 2 teens found dead in an Arizona National Forest; Convictions for illegal BASE jumping in Yosemite; Hikers take cover as shots fly over their heads in a wilderness area in California; Seeking information for an assault at an NPS campground; Justice served for the murder of a man found dead in a wilderness area in Colorado; A man arrested for murdering his girlfriend and disposing her body in a National Forest.Support the show!For bonus content join our Patreon!patreon.com/CrimeOfftheGridFor a one time donation:https://www.buymeacoffee.com/cotgFor more information about the podcast, check outhttps://crimeoffthegrid.com/Check out our Merch!!  https://in-wild-places.square.site/s/shopFollow us on Instagram https://www.instagram.com/crimeoffthegridpodcast/ and  (1) Facebook

In this episode of the Atomic Anesthesia Podcast, we connected with Dr. David Warren, DNP, CRNA, NP to discuss the unique journey of transitioning from nurse practitioner to nurse anesthesiologist. Dr. Warren shares insights from his clinical practice, case mix, and favorite patient populations while reflecting on how his background as an NP shaped his approach to anesthesia. Listeners will learn how previous advanced practice experience can both prepare and challenge those entering CRNA training, the advantages it can bring to clinical practice, and the mindset needed to succeed in this career shift. Dr. Warren also talks about his own podcast and social media presence, explaining how he uses these platforms to educate and inspire other clinicians. The conversation concludes with valuable advice for NPs considering the leap to anesthesia, making this episode a motivating and practical listen for aspiring CRNAs.Want to learn more? Create a FREE account at www.atomicanesthesia.com⚛️ CONNECT:

BASE jumping is prohibited in all national parks, but a small number of people engage in illegal jumps each year, “often placing themselves, rescuers and other visitors at serious risk,” the NPS said. See omnystudio.com/listener for privacy information.

BASE jumping is prohibited in all national parks, but a small number of people engage in illegal jumps each year, “often placing themselves, rescuers and other visitors at serious risk,” the NPS said. See omnystudio.com/listener for privacy information.

In this episode, Justin dives into the three main types of practices nurse practitioners can build: brick-and-mortar, telemedicine, and hybrid. Whether you're just starting out or looking to grow, Justin shares the real pros and cons of each model, pulling from his years of experience working with hundreds of NPs.He keeps it real with practical tips on leases, marketing, and keeping costs in check, while explaining why the hybrid model might just be the best of both worlds. If you're trying to figure out the right path for your practice, this episode is full of relatable, actionable advice to help you make it happen.

John sits down with Harmony Brownwood, CEO & founder of GreenWorks Inspections & Engineering, to unpack how she grew from zero connections in 2009 to one of the largest independently owned inspection companies in the U.S.—now operating across six states with 11 locations, 2,500–3,000 services a month, and a runway from ~$15M toward $20M in annual revenue. Harmony shares the mindset work that kept her going for 16 months without a sale, the systems that let her scale beyond herself, and why “happy clients + happy team” is the non-negotiable core KPI.They get into how GreenWorks blends home inspections, structural engineering, and environmental services; why market flatness forces true market-share plays; and the playbook for entering new states by leading with engineering/environmental before residential inspections. You'll hear how she measures client experience (NPS, “happy calls,” QC + AI on 80k+ reports), builds SOPs that actually stick, and keeps standards sky-high while still being beloved by realtors, investors, and homeowners.If you want a concrete blueprint for scaling a people-powered, service-heavy org—without PE money, franchising, or letting quality slip—this one's for you.

This week, I sat down with Tess Awal, CX Manager at Dr. Squatch — the men's soap brand that turned natural hygiene into a full-blown lifestyle movement. If you've ever seen their cheeky ads or heard about their viral Sydney Sweeney “bathwater” drop, you already know: Dr. Squatch knows how to make personality a growth strategy.We cover creativity, leadership, and what it really takes to build CX that keeps customers talking. Tess shares how her background in fashion photography and visual merchandising taught her the art of storytelling through experience, and why good CX is a lot like good design — it's about knowing what makes people stop, look, and feel something.She talks about how Dr. Squatch keeps its humor while scaling into major retailers like Walmart, Target, and Costco, and what really went into the Sydney Sweeney campaign that broke the internet. Tess also shares why she believes “bad feedback” doesn't exist when you care enough to listen, and how she ensures customer insights are front and center — even the company's COO reads NPS reports every week. Finally, she explains what the Unilever acquisition means for the brand and why loyal fans have nothing to worry about.If you're building a brand, leading a CX team, or figuring out how to stay human as you grow, this episode is packed with takeaways you can actually use. Listen now for lessons on creativity, brand voice, and why humor, empathy, and authenticity never go out of style.

Ghostly holiday parties, dancing desert lights, and a low‑tide cave with a mind of its own. Ready to let curiosity win for one spooky night? In this episode, we cover: Halloween traditions in and around the parks! El Tovar at Grand Canyon and the friendly specter of Fred Harvey Big Bend by night, unexplained lights, and why it can feel like the loneliest park in the lower 48 Acadia's Devil's Oven sea cave, low tide, and why the NPS wants you to give it space Your task for today: We hope we've convinced you that there's a lot more to our national parks than meets the eye! Head over to the @DirtInMyShoes Facebook or Instagram pages and let us know what you think. What's your favorite spooky story from a national park? Planning your own spooky adventures? Dirt In My Shoes National Parks Itineraries: https://www.dirtinmyshoes.com/national-park-trip-itineraries/  Master Reservation List: https://www.dirtinmyshoes.com/list/ National Park Checklist: https://www.dirtinmyshoes.com/national-parks-checklist/  Trip Packing List: https://www.dirtinmyshoes.com/pack/ Don't miss the full show notes packed with all the links we mentioned so you can plan your adventures like a pro: https://www.dirtinmyshoes.com/haunted-national-parks-vol-3/

Translink Nordic Tech Stars | #negotiator 356. Interviews with participants of Translink Corporate Finance Nordic Tech Stars event in Helsinki, attended by premier investors and Nordic SaaS and technology companies. The event took place at Savoy restaurant.00:00 Sami Miettinen intro to Translink Nordic Tech Stars00:32 Guests from Paris: Marc Irisson (Translink) & Elie Hodara (InfraVia)01:04 Shout-outs: Lyyti, Vastuu Group, M&M Growth Partners01:41 Interview: Marc Irisson – trends in B2B tech/TMT02:14 Polarized M&A market; deal volumes US vs. Europe02:50 Polarization inside tech: what it means03:15 Flight to quality accelerates since 202303:53 Multiples: 20× EBITDA / ~10× ARR for top assets; others lag04:36 PE dry powder; opportunities for strong-KPI SaaS05:01 Good vintage analogy for investing/exits05:25 Nordic SaaS quality & Rule of 40 call-out05:57 Nordic/Finnish leadership & international scale06:53 Petri Hollmén (Lyyti, Vaaka Partners portfolio)07:33 Hitting the Rule of 40 sustainably07:59 NPS & eNPS stay high while scaling08:25 5M+ ARR club; revenue levels09:01 B2B SaaS positioning; international expansion09:33 Finnish business community & Turku angle10:09 Tero Nummenpää birthday party with Lyyti10:54 Harry Brade (M&M Growth Partners)11:22 AlphaSense: ARR journey & valuation milestone11:54 SiloAI: early stage to breakout12:17 Flexible tickets; strong AI focus12:57 Vertical vs. horizontal AI plays13:33 SaaS multiples: vertical vs. horizontal (market view)14:13 Entry expectations vs. realized outcomes14:32 Spinning off SiloGen (product vs. services)14:57 Compute, LLMs, and infra as value drivers15:25 Niilo Pirttijärvi (Inven)15:54 AI-driven B2B analytics; who it serves16:18 Market/platform analysis use cases16:44 Funding rounds (pre-seed → Series A)17:10 Notable investors such as Tuomo Vuolteenaho17:31 Global ARR mix (US/EU/ROW)17:57 Rule of 700 growth quip18:15 Product investment & scaling18:32 CAC/NRR/churn & profitability lens18:57 AI ecosystem/community notes19:21 B2B SaaS model durability20:02 Growth vs. cash flow; metrics that matter20:32 Gross margin, usage costs, CAC multiples20:55 Building customer success at speed21:11 Founding team split & coding ambitions21:41 Pekka Vanne (Vastuu Group)22:00 Hartwall Capital partnership22:24 ~90% recurring revenue profile22:43 Consulting components at onboarding23:04 Mission: responsibility & ESG enablement23:22 Meaning of Vastuu, culture23:40 International guests & go-to-market24:00 Growth in Finland; expanding offerings24:26 M&A as an internationalization lever24:46 First acquisition done; more considered25:13 Elie Hodara (InfraVia Partners)25:36 Flexible minority/majority; pure B2B software; GIP platform support26:06 Team footprint; value-add (search, cyber, legal)26:35 Sector themes; why Finnish SaaS scales early26:52 Capital-efficient mindset & early structuring27:09 What founders seek (scaling support)27:25 Biz-dev help; Scandinavia & Europe27:44 Depth across Finland (not just Helsinki)28:33 Rule of 40: useful proxy, not a hard screen29:07 Tracking over hold; context matters29:49 Translink Corporate Finance in tech space30:20 Contact www translinkcf dot com or fi30:52 Subscribe to Translink SaaS Valuation QuarterlyWatch all Insider episodes and support Samihttps://www.youtube.com/channel/UCRI34L9OtDJuZpaWicbNXzg/join#neuvottelija #negotiator Sami Miettinen

Ben Alarie spent 8 years building Blue J with "partial product market fit"—real customers, real revenue, but no real market pull. Then he made a bet that would either kill the company or 10x it: he put the existing product in maintenance mode and gave his team 6 months to rebuild everything from scratch using a technology that barely worked.Two years later, Blue J went from $2M to $25M in ARR. They're adding 10 new customers every single day. NPS went from 20 to 84.This isn't a story about getting lucky. It's about a founder who knew—with absolute conviction—that the market would eventually arrive, and made sure he was ready when it did. But it's also about the danger of fooling yourself into thinking you have PMF when you only "kind of have PMF."Why You Should Listen:Learn the brutal difference between fake and real PMFDiscover when to abandon millions in existing ARR to go all-in on something elseWhy "time to value" might be the single most important metric for word-of-mouth.See what it takes to survive until the market is ready.Keywords:startup podcast, startup podcast for founders, product market fit, founder journey, early stage startup, startup pivot, AI startup, SaaS growth, founder advice, hypergrowth startupChapters:(00:02:00) Starting BlueJ(00:9:26) Introducing AI to Tax Research(00:12:44) Starting to Build(00:17:03) Not Having True PMF(00:19:44) Believing in Retrieval Augmented Generation(00:25:34) Updating to V2 of BlueJ(00:30:58) The Necessity of Time to Value(00:33:47) When You Knew You Have PMF(00:38:19) One Piece of AdviceSend me a message to let me know what you think!

Disappearances in GLACIER National ParkBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

Dean thought he'd have to bootstrap Axonius because no investor would fund a solution to a problem that had existed for 20 years. He was wrong—they've raised $500M. The breakthrough came when a Fortune 500 company was actively being hacked by Chinese state actors. Their first customer almost said no—they had 20 bugs during the POC. But Dean's team fixed each one within 48 hours while their competitors took quarters to respond. That speed changed everything. They went from zero to $100M ARR in under 5 years, created an entirely new category (cyber asset management), and achieved an NPS score in the 80s—unheard of in cybersecurity. His framework for the three types of enterprise journeys will change how you think about positioning.Why You Should Listen:Why responding to customer issues in hours changes everything.How to turn a "dormant pain everyone accepts" into a $500M+ company.Why speed beats everything.The 3 types of enterprise software journeys and which one VCs won't fund.Keywords:startup podcast, startup podcast for founders, Axonius, Dean Sysman, cybersecurity startup, enterprise sales, Unit 8200, cyber asset management, B2B SaaS, YC alumni00:00:00 Intro00:02:25 From Hacker to CyberSecurity00:14:46 The three types of enterprise software journeys00:18:41 Why time to value beats everything00:29:33 Thought they'd bootstrap but VCs validated the problem00:35:14 Failed POCs and landing first customer with 20 bugs00:40:10 Zero to $100M ARR in under 5 years00:45:24 When to know you have product-market fitSend me a message to let me know what you think!

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog You can convince yourself of a fairy tale that the US government provides us with excellent advice on how to be healthy—for instance, what the percentages of each food group should be, like the food pyramid or the food plate. However, time has shown that they aren't focused on our health with their recommendations; rather, they are attempting to promote the food produced in the US. It's all about money. We now understand that the government-approved food pyramid has contributed to an increase in obesity, illness, and diabetes over the last 60 years, primarily because its main goal was to promote grains in the form of cereals to children. This has led to the unfortunate situation we face today, characterized by rising rates of diabetes and obesity.  To make matters worse, iodine has been removed from bread and other foods, leaving many Americans with hypothyroidism.   The allowed food additives extend shelf life (and profits) but diminish human longevity. Ultimately, the government should not dictate our dietary choices! Supplements are substances like minerals, vitamins, peptides, and glandulars intended to enhance the inadequate American diet; however, medical societies and the FDA do not endorse their use. Nonetheless, we need them to improve nutrition, prevent disease, and provide the building blocks for bones and muscles, as well as to counteract the chemicals present in our water, food, and air mandated by the government. Supplements help protect us from the poor advice and environmental pollution we encounter in everyday life. Environmental regulations and processes have resulted in increased illnesses, such as hypothyroidism, due to the addition of fluoride to our water instead of solely to our toothpaste.  Fluoride depletes iodine levels in our breasts and thyroid, contributing to conditions like breast cysts, breast cancer, and hypothyroidism. Regarding water—are you aware that the water treatment managed by our local governments incorporates harmful chemicals into our drinking water, which may be carcinogenic, in an effort to prevent lead from leaching from very old pipes? This system is outdated because most of the population uses copper or plastic pipes, and lead has not been used in construction for more than 50 years. The anti-lead chemicals that are added can adversely affect our health. That is just the tip of the iceberg. Other examples of how our government prioritizes profit over the health of its citizens include allowing big pharma to price necessary medicines beyond the reach of the average person, all to enhance the stock value of these companies. The price of the same drug from the same manufacturer in other countries is significantly lower than for its own citizens. It should be the other way around. Even then, we are sicker and heavier than any other first-world country. Since you are not here to learn about politics, this serves as my segue into discussing the current denigration of the importance of vitamins and mineral supplements for our health. Just consider this:  the average diet consists of processed foods lacking any nutritional value. Fast food contains additives that encourage us to eat more rather than less; portion sizes have increased, and the consumption of whole foods has declined over my lifetime. These are the most compelling reasons I have for taking nutritional supplements that we used to get from our diets before the 1960s. Since we know our patients are consuming chemicals that harm their health, my goal as a preventive medicine doctor, along with my nurses and nurse practitioners, is to keep our patients healthy, even when the government does not!   You should heed our recommendations for specific supplements tailored to your individual symptoms and future health. Public health aims to make the group generically “healthier” by governmental standards, but medical care should prioritize our patients, striving for each individual to live a long, disease-free life. However, we face significant misinformation in this battle! Why don't mainstream medical groups recommend supplements? Their reasons include a focus on illness rather than wellness, making them more reactive than preventive in perspective. Additionally, most doctors lack training in nutrition and are often unhealthy and overweight. Another factor is that they primarily deal with medications and surgeries, which is what they typically recommend. In the twenty-first century, we all need supplemental nutrition.  I don't have a single patient whom I believe is getting everything she needs from her diet without supplements. Supplements include minerals, vitamins, herbs, select foods, and animal glands that help maintain health and prevent illness by compensating for what modern food may lack. The supplements recommended by your BioBalance Health doctor and NPs are tailored to meet various individual needs, so please read about why we prescribe these supplements specifically for you. Supplements add to the nutrients that are missing from our modern diet.   What health benefits can supplements offer? Act as alternatives to medication Enhance the activity of deficient hormones as people age Stimulate the production of hormones Provide the right form of a vitamin that you need and can't get from food Replace the minerals that are lacking in locally grown foods and water Supplements can replace the natural components of drinking water Supplements provide minerals and vitamins that prevent diseases like hypothyroidism. Supplemental animal glandulars are successful at reversing deficiencies that are not available in FDA-approved drugs. Preventive medicine physicians recommend supplements for various reasons: To improve your nutrition To mitigate genetic abnormalities such as elevated homocysteine levels. To counteract chemicals in the environment To treat medical conditions with no known medications To supply certain minerals that are deficient in your area of our country To treat abnormal hormone levels like low thyroid To treat certain symptoms and conditions that have no other solution To prevent future disease To stimulate the production of certain hormones to take the place of a prescription drug To detoxify your liver and gut To improve the absorption of nutrients in the gut To supply minerals and vitamins for osteoporosis To improve your mental health by improving the bacteria in your gut Assist in weight loss My goal is to educate people honestly about the tools they can use to maintain their health and extend their lifespan.  A few words of caution should be added to complete this lesson. Please avoid using the cheapest vitamin or mineral supplement on Amazon unless your doctor has prescribed that specific brand.  Many supplement companies are not “Medical Grade, ” meaning they are not tested and approved by agencies that ensure you receive an effective supplement with your purchase.  Amazon has been found to sell vitamins packaged in reputable brand bottles that contain capsules with none of the expected supplements inside! BioBalance Health and BioBalance Skin provide tested medical-grade products, ensuring you take the right supplements for the desired effect.  We cannot expect the same quality from most supplements available online. Avoid taking a supplement just because someone else is using it; you might not need it, or worse, it could have negative effects. Trust experts to evaluate what you truly need and what you can do without. When you have a consultation with a BioBalance doctor or NP for your yearly visit, please bring a list of your medications and supplements to discuss with them. Please do not call our RN or email your list for their opinion. Evaluating your needs and aligning them with your supplements requires time.

National Park MYSTERIES Collection #22Become a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

Shilpa Reddy, CMO of Down Under School of Yoga and former Marketing VP at Acorns, maps her journey from fintech to wellness and explains why the same principles drive both: make time-tested tools accessible, and build a community that keeps people engaged. She breaks down her three-stage marketing flywheel, and shows why marketers must dismantle the false divide between direct response and brand storytelling. The conversation moves from Acorns' spare-change investing to Down Under's community-driven yoga. She interrogates the role of podcasts as the new TV, the measurement gaps left by ATT, and how authenticity risks becoming uniform in an AI-saturated content world.Questions Shilpa answered in this episode:What drew Shilpa from Acorns to running a yoga business?How curiosity and human-centered marketing let her adapt across industriesWhat is the three-stage marketing flywheel, and how do you know when to move from one stage to the next?Why brand and performance are one continuum, not opposing forces?How LTV makes the case for brand investment with a CFOWhy podcasts function as the ‘new TV' for reach, trust, and ad effectiveness?How marketers should balance host-read storytelling with direct response calls to action?How AT&T's affected mobile marketing measurementWhy authenticity should mean varied storytelling, not uniform brand policingWhat advice Shilpa gives to early-stage wellness founders with no marketing budget?Timestamps:(0:00) – Intro; Shilpa's journey from Acorns to Down Under Yoga(2:00) – Growing up with yoga, curiosity, and career pivots across industries(3:50) – Acorns' mission and how it relates to yoga(8:00) – The three-stage marketing flywheel explained (fit, LTV, brand)(13:50) – Signs you're ready to move between stages (NPS, brand love, data)(15:15) – Making the CFO case for brand investments through LTV(17:00) – The orchestration problem: aligning funnel mechanics with brand reach(19:00) – Podcasts as the new TV: hours consumed, trust, and ad-to-content ratio(24:40) – ATT's impact: creativity up, measurement lagging(26:20) – Authenticity vs. uniformity: the danger of AI-generated generic content(29:30) – Advice to early-stage wellness founders: start with your most loyal clients(55:00) – Wrap-up: Down Under Yoga, on-demand classes, how to connectQuotes:(12:30) – “Stage one is finding who your product is loved by. Stage two is increasing their lifetime value. Stage three is broadcasting your brand story.”(15:30) – “LTV almost by definition is long-term. It allows you to justify investments in brand.”(19:10) – “Podcasts are the new TV. Americans average three hours a week, and the trust in the host feels one-to-one, not one-to-many.”(27:20) – “Authentic does not have to mean uniform. It's the opposite. It means telling varied, engaging stories rooted in what you stand for.”Mentioned in this episode:AcornsDown Under School of YogaShilpa's Linkedin

With the foundational Functional Medicine for Nurses course coming to an end, many nurses are asking, what now? Brigitte Sager, DNP answers that question and maps out the next steps for nurses who want to bring functional approaches into practice. She explains why functional nursing is more than a rebrand, how it reclaims nursing roles as healers, teachers, and leaders, and why nurses need clear scope, community, and clinical support to apply these concepts safely. Brigitte also shares details about the Institute for Functional Nursing, current CE courses, the membership community with live case reviews, and the full functional nursing program launching in early 2026. If you want practical training that is built by nurses for nurses, or if you are wondering how to integrate functional care into your setting, this episode explains how to get started and where to find mentorship and resources. Sponsored by the Institute for Functional Nursing, the premier functional medicine program for nursing professionals. Learn more and join the waitlist at fxnursing.com/learn. Register for the free Redefining the Future of Nursing summit at fxnursing.com/summit.  

Databox is an easy-to-use Analytics Platform for growing businesses. We make it easy to centralize and view your entire company's marketing, sales, revenue, and product data in one place, so you always know how you're performing. Learn More About DataboxSubscribe to our newsletter for episode summaries, benchmark data, and moreDave Gerhardt built Exit Five by treating community like a product—not a side project.In this episode, he walks through how the Exit Five team runs community with the same rigor as a SaaS org: dedicated product roles, roadmaps, feedback loops, NPS, and sprint cycles. He also shares why most B2B companies shouldn't build a community, and what to focus on instead.We also dig into how to justify the ROI of brand and community work, why direct traffic is your best brand metric, and how AI is reshaping what lean GTM teams can do.In this episode, you'll learn:Why Exit Five runs its community like a product orgThe biggest mistakes B2B companies make when launching communitiesHow Drift's podcast helped drive $1M in pipeline – with no attribution modelDave's take on brand, content, and the new AI-powered marketerThe exact metrics Exit Five tracks to grow and retain members

Looking for daily inspiration?  Get a quote from the top leaders in the industry in your inbox every morning.   What's the one premier event that brings the global attractions industry together? IAAPA Expo 2025, happening in Orlando, Florida, from November 17th through 21st. From breakthrough technology to world-class networking and immersive education, IAAPA Expo 2025 is where you find possible.  And, just for our audience, you'll save $10 when you register at IAAPA.org/IAAPAExpo and use promo code EXPOAPROSTEN. Don't miss it — we won't!   Faisal Mirza is the Associate Vice President of the New York Hall of Science. With a career spanning iconic New York institutions—including the American Museum of Natural History, the Intrepid Sea, Air & Space Museum, the Empire State Building, One World Observatory, and even LaGuardia's Terminal B—he has led opening teams, built high-performance operations, and shaped guest experience at scale. At NYSCI, he champions “design, make, and play” through hands-on exhibits rooted in STEM and community impact. In this interview, Faisal talks about the oohs and ahhs, cost-effective vs. better, It's okay to be nice. The oohs and aahs “I think a lot of us have come into this industry because of the oohs and aahs that we are part of… you get those oohs and aahs and you get the wows.” Faisal ties the magic of reveal moments to operational purpose. He recalls One World Observatory's deliberate build-up: from the storytelling elevator ride to a dramatic reveal that regularly prompted applause and even tears. He emphasizes that leaders should revisit these moments frequently—stepping out of the back office to reconnect decisions and data with the guest's emotional response. At NYSCI, that same spark is cultivated by translating concepts into creation. Visitors learn about light, space, or insects, then head into the Design Lab to “use your hands,” turning ideas into tangible projects. That cycle—from discovery to making—keeps guests coming back for the “wow” and reminds teams why meticulous execution matters. Cost-effective vs. better “Should we look into being very cost-effective or being better? There's always balance… it goes back to what the organization is really looking for and how, as a leader, you can justify that process.” When choosing between a sign and a person, Faisal argues that “profitable” and “memorable” aren't always the same. At Terminal B, his team justified human touchpoints (e.g., pre- and post-TSA guidance) by instrumenting the experience with data: NPS, robust passenger surveys at the gate, mystery shops, and large-scale trainings. With measurable outcomes, “better” isn't a vague ideal—it's a defensible investment. He frames the decision as a strategic reflection of organizational DNA. In hyper-competitive markets, small touches compound: clear sightlines, open space, visible staff, and right-sized wayfinding all convert friction into confidence. The lesson for attractions is to define the guest standard, then measure relentlessly so quality choices stand up to budget scrutiny. It's okay to be nice “When you, as part of that team, see, ‘It's okay to be nice. I didn't know that.' When you see others doing it and you're in that universe of everyone being nice, it's really great.” Faisal describes how staffing critical junctions, like the “recomposition” area right after TSA, signals a cultural norm: proactive help is expected. In fast-paced New York, hospitality can still thrive when leaders model it and operationalize it. By placing people where guests naturally feel uncertain, teams normalize courtesy, reduce stress, and elevate the entire journey. That mindset carries into museums and attractions. From shinier floors to warmer smiles, “little things” matter as much as headliners. Faisal's leadership lens blends big-picture reveals with micro-gestures that make visitors feel cared for, proving that kindness is both practical and powerful.   Faisal would like to thank everyone he's worked with over the years, because he's learned something from everyone at the different organizations he's been at. Connect with Faisal directly on LinkedIn, and learn more about NYSCI by visiting www.nysci.org. This podcast wouldn't be possible without the incredible work of our faaaaaantastic team:   Scheduling and correspondence by Kristen Karaliunas   To connect with AttractionPros: AttractionPros.com AttractionPros@gmail.com AttractionPros on Facebook AttractionPros on LinkedIn AttractionPros on Instagram AttractionPros on Twitter (X)  

Host Eric Glazer convenes senior leaders from Humana, Noom, and Blue Shield of California to explore how payers are integrating GLP-1 therapies into comprehensive cardio-metabolic care strategies. The conversation outlines how digital, behavioral, and clinical interventions can align to deliver sustainable outcomes, lower costs, and strengthen member engagement. Panelists share real-world playbooks on scaling GLP-1 programs responsibly—balancing access, affordability, and long-term adherence through consumer-centric design and data-driven clinical support.

These PARK RANGERS Suddenly VANISHEDBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

Best practices once drove growth. But in the AI era, they might be your biggest barrier to progress. Courtney Baker, David DeWolf, and Mohan Rao break down why rigid frameworks like Lean, Agile, and NPS are no match for real-time transformation. They explore how AI is rewriting the rules—and why success now depends on constant reinvention, not static playbooks. David steps into “AI in the Wild” to unpack a headline-grabbing statement from Walmart's CEO: every job—2 million of them—is about to change because of AI. What does that mean for leaders everywhere? Later, Courtney sits down with Andy Sitison, CTO of Share More Stories, to talk about human-centered transformation. They dig into practical AI ethics, how to protect authenticity in a world of generative noise, and what it really takes to build trust with technology.

Why is menopause care still fragmented? Dr. Alyssa Dweck, Dr. Mary Jane Minkin, and Heather Maurer dig into the “menopause desert,” the WHI legacy, workplace fixes, and how NPs and clinicians can personalize evidence-based care—without the stigma or misinformation. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002974?ecd=bdc_podcast_libsyn_mscpedu

Learn how to Master Client Retention with Predictive Analytics Instead of Guesswork Things about client retention that most entrepreneurs get wrong: they're flying blind until it's too late. In this game-changing episode, I sit down with our Director of Community, Walker Renfrow, to pull back the curtain on the client retention strategies we've developed through real-world testing, data analysis, and relentless innovation. We're not talking about the same tired advice you'll find everywhere else—this is about moving from reactive churn management to predictive retention analytics that tell you there's a problem before your clients even know they're unhappy. If you're selling into a leaky bucket and wondering why your MRR isn't growing the way it should, this conversation is going to change everything. Walker Renfrow is one of those rare talents who wears many hats and excels at all of them. As our Director of Community at Predictable Profits, Walker has become a catalyst for growth—constantly innovating, solving problems in unique ways, and creating client experiences that don't just retain customers, they turn them into raving fans. With his background in entrepreneurship and experience across manufacturing, construction, and business coaching, Walker brings a creative, data-driven approach to retention that you won't find in any textbook. He's an artist in both his personal life as a singer and in his professional world, looking at challenges from angles most people never consider. KEY TAKEAWAYS: Selling into a leaky bucket caps your MRR—retention is just as critical as sales for growth. NPS surveys alone won't cut it—low response rates and shallow data won't move the retention needle. Your team can't give accurate client health assessments—their incentives are misaligned to paint rosy pictures. Quarterly interviews by a third party (not the account manager) get you the honest feedback that drives real change. Relationships + Results = Retention—most businesses focus only on results and ignore relationships entirely. Use red/yellow/green client scoring: 75% green, 20% yellow, 5% red—zero red means you're lying to yourself. Track behavioral metrics (attendance, implementation, engagement) to predict churn before it happens—not after. Community is your AI-age defensibility—authentic human connections become irreplaceable as everything else gets commoditized.   Growing your business is hard, but it doesn't have to be. In this podcast, we will be discussing top level strategies for both growing and expanding your business beyond seven figures. The show will feature a mix of pure content and expert interviews to present key concepts and fundamental topics in a variety of different formats. We believe that this format will enable our listeners to learn the most from the show, implement more in their businesses, and get real value out of the podcast. Enjoy the show. Please remember to rate, review and subscribe to the podcast so you don't miss any future episodes. Your support and reviews are important and help us to grow and improve the show. Follow Charles Gaudet and Predictable Profits on Social Media: Facebook: facebook.com/PredictableProfits Instagram: instagram.com/predictableprofits Twitter: twitter.com/charlesgaudet LinkedIn: linkedin.com/in/charlesgaudet Visit Charles Gaudet's Wesbites:  www.PredictableProfits.com www.predictableprofits.com/community https://start.predictableprofits.com/community

Yoon Kim and Kenji Haroutunian are leading the charge with Outdoor Media Summit, a gathering of industry professionals that continues to build momentum after nearly a decade. In this conversation, we dive into the history of the event - and more importantly, where it's headed. They are launching something new at this year's event, and we've got the exclusive on that announcement. Show Notes: Outdoor Media Summit: https://outdoormediasummit.com/ Yoon Kim: https://www.linkedin.com/in/yoon-kim-5027b214/ Kenji Haroutunian: https://www.kenjiconsults.com/ Colin + Samir Episode: https://www.youtube.com/watch?v=hbZbPHjE8NE Erica Zazo: https://www.linkedin.com/in/ericazazo/ Outdoor ECom: https://outdoorecom.com/ Startup Junkie: https://startupjunkie.org/ Global Cycling Accelerator: https://cyclingaccelerator.com/ Stephen Regenold - Founder of Gear Junkie: https://www.instagram.com/stephenregenold/?hl=en NPS: https://en.wikipedia.org/wiki/Net_promoter_score BPC - Brand, Product, Content: Livsn T-shirts: https://www.livsndesigns.com/products/pack-shirt Yoshino Power Station: https://yoshinopower.com/products/b2000-solid-state-portable-power-station FlyLow Homegrown (Book): https://flylowgear.com/collections/all/products/homegrown-the-flylow-story Join us on LinkedIn: https://www.linkedin.com/company/second-nature-media Meet us on Slack: https://www.launchpass.com/second-nature Follow us on Instagram: https://www.instagram.com/secondnature.media Subscribe to our newsletter: https://www.secondnature.media Subscribe to the YouTube channel: https://www.youtube.com/@secondnaturemedia

At WebexOne, John Ortiz, Technology Sales Manager at MiaRec, joined Doug Green, Publisher of Technology Reseller News, to discuss how MiaRec is using AI to reshape the way businesses analyze and improve their customer interactions. MiaRec's platform leverages large language model (LLM) technology to deliver insights across three key use cases: Automated QA: Using AI to review and score 100% of customer interactions, ensuring that agents meet performance and compliance standards while eliminating the limitations of manual quality assurance. CX Intelligence: Automatically generating metrics such as customer satisfaction (CSAT), net promoter score (NPS), effort scores, and churn risk, giving companies a real-time understanding of customer sentiment and retention trends. Revenue Intelligence: Tracking sales opportunities and performance metrics across calls — including upsell and cross-sell effectiveness, objection handling, and missed revenue potential — to help managers identify top performers and training needs. Ortiz emphasized that the platform's customizable LLM framework allows businesses to extract any metric they need, regardless of industry or use case. “Every customer we get has different goals,” Ortiz said. “Having the flexibility to extract custom insights is absolutely key.” MiaRec integrates seamlessly with leading communication platforms such as Webex Calling, Webex Contact Center, RingCentral, NICE, Five9, and Twilio, while remaining platform-agnostic for clients with mixed environments. To learn more, visit www.miarec.com.

In this Bright Spots in Healthcare episode, host Eric Glazer brings together an all-star panel of leaders who are reshaping the future of Medicaid and social care. Our guests include: Vanita Pindolia, Vice President, Medicare Star Ratings, Emergent Holdings (BlueCross BlueShield Michigan) Jason Merola, MD, Chief Medical Officer, MVP Health Care Charlotta Eriksson, Lead Director, National VBC Partnerships (Specialty), Aetna Mary O'Connor, MD, Chief Medical Officer & Co-Founder, Vori Together, they explore: How Medicare Advantage plans are embedding Stars, CAHPS, and adherence metrics directly into provider contracts to drive accountability, improve quality, and sustain year-over-year performance gains. How payers like Aetna are expanding value-based care into specialty domains—from CKD and oncology to musculoskeletal and cardiology—by partnering with specialty-aligned organizations rather than converting individual specialists to risk models. How MVP Health Care is designing hybrid incentive structures that reward specialists for closing quality gaps and improving outcomes, without requiring full downside risk. Why MSK care is becoming pivotal to Stars success, as physical and mental health measures grow in weight through 2027, and how holistic, physician-led models are improving activity, satisfaction, and cost savings simultaneously. How digital-first specialty networks are solving access challenges, reducing “ghost network” exposure, and creating new opportunities for plans to meet CMS adequacy standards while improving the member experience. How collaboration across utilization management, Stars, and member experience teams helps avoid trade-offs, ensuring that cost controls don't come at the expense of satisfaction or CAHPS performance. Panelist Bios: https://www.brightspotsinhealthcare.com/events/stars-savings-and-satisfaction-unlocking-msk-and-specialty-care-strategies-for-medicare-advantage-success/ Download the Episode Guide: Get key takeaways and expert highlights to help you apply lessons from the episode. https://drive.google.com/file/d/1a_rX23Ev5VRrJKqb8_UwAYBd9tUBIfWA/view?usp=sharing Resources:  Maximizing 2026 Medicare Advantage Performance with Physician-Led MSK Care This report outlines how Vori's physician-led, virtual-first musculoskeletal (MSK) model helps Medicare Advantage plans:Improve up to 12 Star measures across preventive care, chronic condition management, and member experience Deliver faster access to care—appointments available within 48 hours Enhance outcomes for pain, fall prevention, and osteoporosis care while achieving an NPS of 87 Align with the new 2026 Star measures for Improving and Maintaining Physical and Mental Health To request your copy, email nroberts@brightspotsventures.com. Clinical Quality Performance of Value-Based and Fee-for-Service Models for Medicare Advantage: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2839238 This JAMA Health Forum article compares clinical quality outcomes for Medicare Advantage patients whose care is delivered under value-based payment (VBP) models versus traditional fee-for-service (FFS). It finds that VBP arrangements, especially those with two-sided financial risk—in general are associated with better performance on standardized clinical quality measures than FFS. Thank you to our Episode Partner, Vori: Vori partners with health plans and providers to improve musculoskeletal (MSK) care through data-driven, physician-led solutions. Their approach helps reduce unnecessary surgeries, improve recovery outcomes, and enhance patient satisfaction—supporting plans in achieving better Stars performance and overall member experience. To learn more, visit vorihealth.com. Schedule a meeting with Mary O'Connor Chief Medical Officer, Vori: To dive deeper into how Vori can help your plan improve outcomes, reduce costs, and strengthen Medicare Advantage Star Ratings,or to schedule a meeting with Mary O'Connor. Reach out to nroberts@brightspsotsventures.com  to schedule the meeting. About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation.   We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the “bright spots” in healthcare, proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.  

Crater Lake–impossibly blue, ancient, and eerily still. It's a place born from fire, shaped by collapse, and steeped in legend. But in the fall of 2006, this sacred landscape became the backdrop for one of Oregon's most heartbreaking mysteries–the disappearance of an eight-year-old boy who seemed to vanish into thin air.Autism Anchoring Dogs is no longer in operation. Please see below for a list of other service dog organizations;https://www.autismspeaks.org/assistance-dog-informationEpisode Sources;USA Today, Facebook, Autism Anchoring Dogs, Strange Outdoors, People, More Than Just Parks, YouTube, Travel Medford, NPS, Crater Lake Institute, Crater Lake Institute-2Support us on Patreon for as little as $1 a month, with benefits starting at the $3 tier!Follow us on Instagram at offthetrailspodcastFollow us on Facebook at Off the Trails PodcastIf you have your own outdoor misadventure (or adventure) story that you'd like us to include in a listener episode, send it to us at offthetrailspodcast@gmail.com  Please take a moment to rate and review our show, and a big thanks if you already have!**We do our own research and try our best to cross-reference reliable sources to present the most accurate information we can. Please reach out to us if you believe we have mispresented any information during this episode, and we will be happy to correct ourselves in a future episode.

前半はDaft Punk「One More Time」の元ネタ分析や、音楽制作ツール「Tracklib」の見せ方に感心しつつ、サンプリングの創造性についての考察。後半は、カスタマーサポートへのポジティブなフィードバックから始まる「うれしすぎる」やりとりが、事業者と利用者の間に前向きな循環を生むことや、フィードバック文化に見る国民性の違いについて話しました03:09 音楽制作ツール「Tracklib」の見せ方がうまい − 既存曲の波形とどの部分をサンプリングに使っているか可視化03:43 Daft Punkの「One More Time」のイントロの作られ方の巧みさにびっくり − 1979年の曲のサンプリング05:32 プロミュージシャンに聞いたTracklibとサンプリングへの考え方09:45 コーヒーメーカーに「美味しすぎる」と感想を送ったら「嬉しすぎる」という返事がきた（1億ビュー超え）10:50 牛の匂いが落ちまくりすぎる洗剤→「うれしすぎる。開発チームに伝えすぎる」→「牛、栄えよ」12:00 良いフィードバックはサービス提供者側のモチベーションを上げ、機能開発にも反映12:50 日本のアプリストアのユーザーレビューは世界で突出して低い（ことで有名）13:47 間違った店を指定していたことに気づいたとき、タクシー運転手が料金そのままの神対応18:13 否定的な言葉を肯定的に言い換えるビジネススクールの訓練は、受け手のメンタルを変える20:51 NPSスコアの国民性の違い：9-10が「OK」なのに対し、日本人は5-6を「普通」と思って付ける25:23 アメリカの病院アンケート：質問数80（！）、受付から医師の対応まで細かく聞かれる27:59 ロックバンド「GLAY」が30周年ライブ後に実施したファン向けアンケートがすごくちゃんとしてた32:04 フランス人はまず批判を先に言う。アメリカ人は最初は褒めるのでフィードバックが全然伝わらない34:37 言い方の順序、強調するポイントをその言語向けに最適化することが重要（言葉を翻訳するだけではダメ）エピソード内で取り上げた情報へのリンク： Daft Punk「One More Time」イントロでのサンプリングの使われ方 1990〜2024までの有名曲のサンプリング集 1億ビュー超えのX投稿 国民性によるNPS評価の違いテック業界で働く3人が、テクノロジーとクリエイティブに関するトピックを、視点を行き交わしながら語り合います。及川卓也 プロダクトマネジメントとプロダクト開発組織づくりの専門家 自己紹介 ep1, ep2 関信浩 アメリカ・ニューヨークでスタートアップ投資を行う、何でも屋 自己紹介 ep52 上野美香 マーケティング・プロダクトマネジメントを手掛けるフリーランス 自己紹介 ep53 https://x-crossing.com

GOLD Updates, Novel Treatments, and Managing Comorbidities in COPD Care Level up your COPD care with practical, evidence-based strategies. Learn how to confirm airflow obstruction with spirometry (and use LLN/Z-scores thoughtfully), stage patients with the A/B/E framework, and build treatment around long-acting bronchodilation—adding ICS selectively based on exacerbations and eosinophils. We'll highlight the nonpharmacologic moves that change outcomes (smoking cessation, vaccination, pulmonary rehab, oxygen when indicated), when to reach for add-ons (azithromycin, roflumilast), how to approach chronic hypercapnia with home NIV, and what's new (hello, ensifentrine). Pulmonologist and longtime Curbsiders member Dr. Cyrus Askin (@Askins_Razor ) returns to share real-world pearls for diagnosing, treating, and managing comorbidities in COPD. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 Diagnostic Workup Understanding the Ratio, LLN/Z-Scores, and Equity Symptom abd Risk Staging (A/B/E) Case 2 Foundational Care  Initial Inhaler Strategy  Progression & Hypercapnia: NIV & Adherence Counseling Add-On Pharmacologic Options for Frequent Exacerbators What's New and Emerging Comorbidities and When to Refer  Take-Home Points Recap Plugs, CME, and Credits Credits Written and produced by Paul Wurtz MD. Show notes, cover art, and infographic also created by Paul Wurtz MD. Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cyrus Askin MD   Sponsor - Freed Use code: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor - Grammarly Sign up for FREE and experience how Grammarly can elevate your professional writing from start to finish. Visit Grammarly.com/podcast Sponsor -Locumstory Learn about locums and get insights from real-life physicians, PAs and NPs at Locumstory.com

What if the biggest threat to next year's revenue isn't churn—but the quiet erosion of loyalty you never saw coming? With 85% of professional services revenue riding on existing clients, old tools like NPS and gut instinct just won't cut it anymore. In this special edition, we're taking you inside the Knownwell platform itself—no roundtable, no guests—just a front-row seat to how real-time commercial intelligence is changing the game. Knownwell Chief Marketing Officer Courtney Baker and Chief Product and Technology Officer Mohan Rao walk through the platform live, showing how executives can go from blind spots and firefighting to confident, data-backed decisions in minutes. Watch as they simulate a Monday morning at a fictional agency—and reveal how Knownwell helps leaders prep for surprise client calls, uncover hidden growth opportunities, and balance energy across a full portfolio. This isn't just a product demo. It's a blueprint for how high-performing teams are staying ahead of risk, strengthening client relationships, and winning renewals—without the guesswork.

יש לנו יותר דאטה מאי פעם על הלקוחות שלנו, אבל האם אנחנו באמת יודעים מה הם מתכננים לעשות? מודלים לחיזוי נטישה יכולים לספר רק חלק מהסיפור. דרך הבלוג שחיברה מיכל מילר לוי, Head of market research and insights במאנדיי, נגלה שהמפתח להבנת הכוונות האמיתיות של הלקוח טמון במשהו אחר לגמרי: ויראליות, או במילים פשוטות, האם הם ממליצים עלינו לחברים וקולגות. בפרק נציג מתודולוגיה יישומית המשלבת בין מדדי המלצה (כמו NPS) ושאלות ישירות על התנהגות, כדי ליצור את "מטריצת ויראליות-נטישה" ונלמד כיצד למפות את הלקוחות שלנו לארבע קבוצות התנהגות. אז הצטרפו אלינו כדי ללמוד איך לזהות את קבוצות הסיכון מראש ולפעול בצורה ממוקדת כדי לשמר לקוחות ולהזניק את הצמיחה.See omnystudio.com/listener for privacy information.

They VANISHED: Park RangersBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

Sarah Aswegan, a seasoned biopharma leader and strategic advisor for global rare disease solutions, shares her journey from sales in pharma to her consulting work today. She discusses her experience in transitioning biopharma companies from clinical to commercial success, the evolution of medtech in diagnosing and managing rare diseases, and the collaborative efforts required to bring innovative treatments to market. She also shares insights on current trends in gene therapy, the dynamics of funding, and the importance of data in advancing care for rare disease patients. Guest links: www.saraaswegan.com  Charity supported:  Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 065 - Sara Aswegan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and today I'm delighted to welcome to the show, Sarah Aswegan. Sarah is a seasoned biopharma leader helping organizations transition and grow from clinical to commercial success. She prides herself on the success of leading multiple global cross-functional teams and contributing to the success of the franchise areas she oversaw and served. Until recently, she's applied these experiences while serving in a consultancy capacity for many small to midsize biotechs entering or expanding in rare disease. She has also successfully helped organizations to start and scale adjacent spaces to biopharma, and most recently has been serving as a Global Head of Commercial Assets, Brands, and Care Solutions, and has led transformational change at UCP, having been part of the design and scale of the business unit for rare disease. She maintains a strong network among clinicians, access, bioethicists, and patient advocacy globally. Well, thank you so much for joining us today. I'm so excited to speak with you. [00:01:52] Sara Aswegan: Thanks, Lindsey. It's nice to be here. [00:01:54] Lindsey Dinneen: Wonderful. Well, I'd love, if you wouldn't mind, sharing a little bit about yourself and your background and what led you to medtech. [00:02:02] Sara Aswegan: Yeah, thanks Lindsey. You know, I, I started my career ages ago in the pharma side of things, and as my career has grown, so has the exposure across pharmaceuticals, into biotech and including aspects of medtech. As we look at some of the areas I've spent the last 18 years in rare disease, the medtech component is coming in largely around if we think about the diagnosis component and then the management of the different conditions over the lifespan of a child or adult affected by a rare condition. You can see things really evolving. I started my career on the sales side of things. My education is in business and communication, so anyone can learn the science if you have good mentors and people to help you along the way. And I was really, really fortunate to work amongst a team of amazing individuals, both in the US and then now having lived away for about 15 years outside of the US that have helped open my eyes to what can be possible and the differences by markets. And as I mentioned, I spent the last 18 years in the rare disease space really helping companies of all sizes build out and scale their teams, bringing in new assets and bringing solutions to the field of rare disease. And it's something I'm very passionate about. [00:03:06] Lindsey Dinneen: Yeah. Well, thank you for sharing a little bit about that. So I'm curious, that's a very specific niche and I would love to understand how you arrived at that and how you realized, "Oh, this is what I'm meant to be doing." [00:03:19] Sara Aswegan: Yeah. So I made a move geographically and company-wise to a small firm at the time. We were just a very small team. We called it the bootstrapping team at Shire Human Genetic Therapies, and I moved from the Chicago area to Boston, and that was my first really exposure to rare diseases. And, it's a completely different field and it continues to evolve even to this day. But the closeness and proximity you have to patients and their families and those with unmet need. And I have, you know, a couple of close friends as well as a family member that's been affected by a rare disease. So as you're seeking care and support for them, it's not always about the medications. It's about that total person and thinking really holistically about the individual and their care teams that are impacted by those conditions. So the external community we were serving really drove me and introduced me to something that I've stayed with, and it brings great passion to try to find ways to support individuals in our western society, but also looking at low middle income countries and helping facilitate diagnosis to treatment to, again, that whole supportive care and largely from the internal teams within the organizations I've worked with has just is been tremendously rewarding and also equally challenging. It's beautiful to see progress. I mentioned diagnosis and. One of the areas I worked in initially was in the lysosomal storage disease area. And it's the age-old question on diagnosis. Do you facilitate newborn screening, for example, so when your child is born, you have a heel prick done and you can do a series of tests depending on the state you live in, and in some countries in Europe it's also provided. But if there's not a therapy, is it okay to do that type of diagnosis support. And so that challenge, you know, in seeing the policy evolve on a state by state basis. When I began in the rare disease space and MPS Type Two Hunter Syndrome, it's a condition that affects mostly boys and a very small part of our population. We knew we could do newborn screening and there was a therapy available, but it wasn't only realized until a few years ago to introduce newborn screening to help those families at the point of birth to know if their child was affected, and therefore start a different trajectory on how they planned for care for them and plan for if there was a medication or other supportive tools and resources available for them. So it's been extremely dynamic to see how things have evolved. And then now as you see medical and pharma medical technology advance as well into gene therapies. You're seeing news about gene therapy and it's a one time treatment and then the individual hopefully will not have be re redos in their lifetime. Along with that come challenges on that diagnosis piece to make sure they're eligible for the gene therapy. So again, through the device and technology sector, it plays a key role. In addition to the supportive care that goes on for some of these really severe conditions, people have some pretty dynamic needs and it's great to see how things are progressing, but it's still as equally as frustrating, whether you're on the manufacturer side or the family side, to see things be kind of slow sometimes. [00:06:15] Lindsey Dinneen: Yeah, of course. And you're dealing with a specific situation where many times-- please correct me if I'm wrong-- but it seems like many times there's these kinds of studies and conditions are not funded very well in terms of finding solutions to the problem. So how is that something that you, well, first of all, of course we're in a very interesting season of life right now. So how are you seeing funding evolve over the years for these different diseases that are a little bit more rare, and what can we all do in terms of even just awareness and understanding? [00:06:51] Sara Aswegan: Yeah, so that's a huge question. We could probably have about five conversations on this just to scratch the surface, Lindsey. I think if I reflect on the question on what we've seen around funding, I mean there are some wonderful, supportive grants available for the brilliant scientists we have around the world that have a curiosity. So making sure we can facilitate that ongoing academic environment to explore and test the hypothesis. And one of the things that you see coming along, and it's not really around-- I won't think about funding as just pure financial-- but it's the funding of the smarts that go around the table. You see a lot more collaboration amongst academia, industry governments coming together to help build and scale so that there's an awareness and understanding of a condition. I mean, a pediatrician could go through their entire career and never see a boy with Hunter Syndrome. It's just that rare. At the same time, and on the converse of that, if you're working in an industry where you do have access to more funds, the introduction of AI and looking at how we look at drug targeting, drug target selection, genetics and precision medicine have come along quite leaps and bounds in the last several years, but we're still not quite there. But you're seeing advancements with the different cell and gene therapies, having that precision medicine as an option. It's coming forward. The challenge is the size of studies are normally very small because the population is small. So thinking about patient recruitment, how can we help facilitate better identification of individuals that may be out there and not have received diagnosis because of the rarity of the condition? So looking at technology and advancement of integrated electronic health records up to and including, how do we look at the trial designs? And how do manufacturers, academics, industry, and agencies work together to think a little differently around even designing clinical endpoints for the studies that really are meaningful, that will make a difference. And how do you balance that, right? Correct risk benefit conversation, in the spirit of doing no harm. But if there's one chance and there's something available, how do you do that? And coming all the way downstream. If you think about where the organizations have advanced their thinking, their approach, and put funds behind, it's also that ongoing care of the individuals. If you look at the upstream, the types of tests that are available. It could be cancer, it could be the area I am so passionate about in genetic disorders, but it can also be thinking about the workflows that come into play in helping facilitate consistency of care across state borders, across country borders. It's a key piece that are really advancing in real time, but we're still trying to overcome the hurdles that are real. And that's things around data privacy. How do we navigate that in a really meaningful way with the right ethics and integrity. If we think about the regulators, this isn't a huge anti-infective or cardiac study that's ongoing, that there are gonna be tens of thousands of people. So how can we think a little bit differently on advancing the care. In the area I'm working in, Lindsey, especially with some of these individuals that are kids, if they don't get access to care by a certain age point, their window of treatment has closed. And so what could we do to help facilitate earlier diagnosis and then that advanced care. And so I think we can see a lot of really good intentions, and I think the most beautiful thing is even the collective gathering of different patient organizations that have a shared interest of a disease coming together and also helping raise research funds to help support the scientists that have a hypothesis on something that may really make a difference and may matter. [00:10:21] Lindsey Dinneen: Yeah. Yeah. Okay, so, there has been so much innovation in the last few years-- of course, even before that, but it seems to be extremely exciting in the last few years-- especially things like CRISPR and all sorts of new technologies emerging. What are some of the exciting trends that you're seeing in this space specifically that give you hope as you continue to look forward and look for solutions? [00:10:45] Sara Aswegan: I think for me, I mentioned, I touched on it lightly. I think it's that collective, that collaboration and the openness now. The FDA has advanced the way that they think and engage with agencies as well as industry partners. And so what I mean by that, Lindsey, is they're not just engaging with the scientists or with the manufacturers, the drug developers. They're also bringing patients in. And so that collaborative environment, they're even beginning conversations when there's discussion on clinical trial design to understand what really matters. Is it a six minute walk test or is it something around real behavioral or other abilities that can be learned and retained over time that help benefit the quality of life? If you're not gonna be able to cure something, what's really important at that patient front to help facilitate something meaningful. So I think that type of conversation also with the agencies looking at, there was an amazing session held in Europe recently in the mucopolysaccharidosis or the lysosomal storage disease area, looking at advancements of science and saying, can we look at biomarkers alone and create that relationship and understanding there is a clinically meaningful impact if we can address this biomarker. And so, companies like Ultragenyx have really pushed to have that conversation and dialogue and have a drug filed now that's under review based on biomarker endpoints alone, where five years ago, you would never have imagined that being possible. [00:12:12] Lindsey Dinneen: Yeah. Yeah. You touched on something that I would really love to explore a little bit deeper, and that is, when there's a situation that right now we don't have a cure for this disease-- and, you know, obviously we're still working towards it-- but if we don't have a cure, but we are trying to improve the quality of life, how do you balance that in your specific field in terms of: obviously you want the patients to live the best quality of life that they can while balancing so many other, and I don't mean this in a callous way at all, just from a practical perspective, balancing all of these other considerations and things that are also desiring funding and all those competing priorities. So how do you balance that? How, how does that come into play? [00:12:57] Sara Aswegan: So that's a big one. It's a tough one. And I'll oversimplify it and just say data. And what I mean by that, Lindsey is really looking at, with the technology at our fingertips, regardless of the geography you're living in, there's a lot of meaningful information that can be captured. And it's not, again, around one aspect of a disease, but it's the totality of health. So really looking at what could be possible in capturing, is it around energy levels, activity levels. And you'll see that oftentimes in play with the gene therapy, for example, when it's administered, you may have up to 15 years of follow up that you're capturing specific data points. But even in advance of a drug approval, and an area I am also equally passionate about, is access to unlicensed medicines for individuals that can't travel to a clinical trial site and could benefit from an investigational therapy, how do we do that with the right balance in place? And part of that is data and having the willingness of a participant or family member to be so consented in and participating in the study for their child to share that data and share that real world data or real world evidence so that you can measure back and show what impact that drug or treatment or intervention has been having on the individual. So I think it's around that and figuring out how we can overcome some of the complexities and challenges that are real. Not everyone has electronic health records. There's still lots of paper-based offices out there. But in the meantime, there's a lot of advancements in technology. So how do you appropriately use that, that it's also not overburdensome for the individual, for the family as well, that you're doing what really matters and measuring back and having the right conversations with the individuals affected, the investigators, the clinicians, but then the regulators, and going back and sharing why this can be something to help substantiate. It's not your standard phase 1, 2, 3 clinical trial design. That's, yes, there's rigor, but it's a different way of looking at using data to help us advance our understanding of a disease and what's needed by the individual affected. [00:14:53] Lindsey Dinneen: Yeah. So, so when you're speaking with these families and or-- well, first of all, let me actually back up. Do you have direct communication with some of these families and patients that you're working with? [00:15:04] Sara Aswegan: Yes. [00:15:05] Lindsey Dinneen: Yeah. And so when that happens, how. How is it for you? I mean, this is such a challenging area that you have devoted your life to and to, and I'm so impressed with that. And, you're doing the work that's helping save lives and make a difference. But that must be really challenging from a personal level to have these difficult conversations. So how do you balance that as a practitioner and somebody who's desiring to help, but you also have this real life compassion and human being that you're trying to help? [00:15:38] Sara Aswegan: It's tough and it's tremendously rewarding. At the same time, I have so many patient stories I can share with you of meeting them and meeting 'em where they are. I made a trip to Sao Paulo, Brazil once, Lindsey, and met a family that were living in the favelas there, and their aim was to help raise awareness for Hunter's Syndrome because their son had been undiagnosed. They knew something was wrong. He was nonverbal. He had some physical presentation that you could understand. There was something going on, but the technology wasn't there for them. The access to the care center wasn't there for them to get a diagnosis. They were taking buses for hours to different clinics to figure out what's wrong with our son. And he finally received a diagnosis of Hunter Syndrome and they wanted to share the photos because kids with Hunter Syndrome do have some different dysmorphism. So there's something that's strange. They have a bossy forehead, or their bridge of their nose is a little different. Their bellies might be a little bit bigger. So if you start looking at all of these different clues and putting it together, you might suspect and go-- there's other things going on, for sure. So I'm oversimplifying this. However, getting a diagnosis for him by just raising awareness to other families of the physical presentation and what their experience was extremely meaningful for them. And on balance, a family in Florida that I met and their son was diagnosed at age 18 months because their grandmother had seen a program on Mystery Diagnosis and said, "That sounds like my grandson." And so creating the conversation and meeting people where they are is really important because you may have some individuals that are very aware of how drugs are developed and all of the rigor that goes through that to then others that just they don't understand that some drugs are intended for a specific indication, specific population, and helping explain why their child may not be eligible for a particular study. It's tough, and that's not my responsibility, but the clinical teams and the clinicians that are having those conversations. So it's listening and really coming with a open heart and mind and having empathy to help figure out how can you educate. It's even moving into gene therapy. What does gene therapy actually mean? What are the risks? I'm afraid this sounds like it's something so futuristic. What will this mean for my son or daughter in 10 years from now? And, we may not have all of the answers, but you know, science has advanced and it's that risk benefit that you have to exercise. But really it's that coming with compassion and a listening ear and understanding and being honest. And if I can't help, maybe there's someone else that can help or there's a, did you know, there's a clinic here or a center there and helping that network stay connected and thrive is really important. And also being their voice, Lindsey, I mean, we can, we have an opportunity on our pharma, biomedtech side of the world that we can share what we've observed and try to apply that as we come to work every day and think about that family we met in Brazil or in Boston or in Florida or in, you know, Frankfurt, and whatever they may be experiencing. So it's being their advocate in other areas as well. [00:18:34] Lindsey Dinneen: Yeah, exactly. So with what you deal with, I am wondering what kinds of misconceptions or myths do you often encounter that are interesting and yet you would prefer to correct so that those of us in the general population are more informed? [00:18:52] Sara Aswegan: That's a good one. So I think having worked in the rare disease space, one of the biggest scrutinies there, there's on two sides of the coin. One is around diagnosis and why we can't do more around diagnosis. And sometimes the science is just not there yet. So again, to some of these experiences, like the story of the family in Brazil, it may not be about a blood test. It may be about a physical appearance and helping people piece things together. I think on the other end is at the point of delivery of the diagnosis and then if there is a treatment or intervention that can be taken, and not everyone has the same principle in their heart. There are companies that are motivated for different reasons, but certainly the big topic is are around drug prices, whether it's a gene therapy or a chronic lifetime medication, of how do we navigate that and how do we navigate that in a better way? And I think we have to start looking as an industry, as a community of people, of how do we address that? The cost of doing a clinical trial is tremendous. It's hugely expensive. Does it warrant though huge price tags on drugs forever in perpetuity? What's that right balance? And I think having a level of social responsibility and looking at alternatives. And so imagine if we could reduce the time for clinical studies for requirements because we're able to look at other data. Things like the biomarker approach and the follow on real world data that could be captured, could that help us in the total overall offering and the cost to the overall health system? Maybe. I think that as an industry, every company operates with different principles and wanting to do best for the patient community. Some are more profit driven than others, and so that's a reality, and it's one that I get so often at dinners with friends or in personal conversations, professional conversations, and it's a tough one. At the same time, a study of 60 individuals could be double digit millions of dollars. Just the cost of facilitating the study, the production costs of some of these highly technical compounds of different therapies also becomes a factor. So you have to put all these pieces together and really explore what's driving that. [00:20:57] Lindsey Dinneen: Yeah, of course. And yes, I'm sure that's a really difficult conversation to have too, when you're especially working directly with patients and trying to explain all of that and that's a lot. That's a challenge. [00:21:10] Sara Aswegan: Yeah. Yeah. [00:21:11] Lindsey Dinneen: But on the flip side, you know, of course the work that you do makes a huge impact, and I'm wondering if there are any stories that come to mind that just really reinforced to you, "You know what? I am in the right place at the right time, in the right industry." [00:21:25] Sara Aswegan: Absolutely. And I think it goes to, I touched on it very briefly, and there are people that aren't living in near major cities, near major medical centers, and that should not make them obsolete from receiving the best care. And there are two things that have happened and partly because of the pandemic, but also partly because of the willingness to educate and have that connected community amongst clinicians, is around that access to unlicensed medicine and finding pathways that it's not just because a doctor says your son or daughter needs this medication. I'm going to reach out to the manufacturer to see if I can get access because they're not near a clinical trial site or they don't wanna participate, or they're unable to participate in a study. But finding means to do that. And there have been some really creative ways that clinicians have been able to do that, of setting up qualified treatment centers where the individual can go to receive the treatment and then that continuity of care is provided then over the life of their disease. It's something that's become real and meaningful, and you would be shocked at the number of individuals around the world that are receiving access to medicines that normally might have only 10 years ago been available if you were living in the Western Europe or the United States because studies weren't conducted in their country and so there's no pathway for access that is all changing. Those dynamics are changing. It takes a team of people, though. It takes regulators, it takes lawmakers, it takes industry. It takes our logistics teams to be sure if something's stored at cold chain, that that product is delivered in the right context at the right time, just in time for that patient to receive it. So it's a complex challenge, but it's one that we've seen serve individuals in a really meaningful way. And without that, they wouldn't have, they wouldn't have another option. [00:23:11] Lindsey Dinneen: Yeah. So having that impact and just being able to reinforce in those moments of maybe when it's especially difficult or you're especially frustrated like, "Oh my gosh, I wish I could help X, Y, and Z," at least you can look back and go, "Yes, but look at all this that we are doing." [00:23:26] Sara Aswegan: You know, Lindsey, also it's that education piece and being curious and asking questions. The scientific community and one of the lead leaders in the NPS community is in North Carolina, Joe Munzer. Dr. Joe Munzer, he's brilliant. And one of the initiatives that we started was something called a masterclass. And so with Dr. Munzer and seven or eight other clinicians from around the world, we literally went on an educational program around the world. And some of the individuals that had just come out of their postgraduate work, pediatric geneticists or neurologists meeting the number one or two people that know this space so well, being mentored by them. And now those individuals are facilitating their class, the same type of class in their local language to their local communities and creating that level of education and awareness. I mean, it's just to see that real impact over time. I actually get goosebumps just thinking back on the impact that has had. And you've got a community of clinicians that they're, I mean, there's a lot of needs still to study medical genetics. And so hopefully we have individuals that are scientifically interested and will continue that that journey so that they can be the next teachers across borders. That makes the difference. [00:24:37] Lindsey Dinneen: Yeah. Absolutely. Wow. Yeah. Thank you for sharing that. I was also getting goosebumps just listening to it because that's incredible ripple effect that you had and continue to have. That's amazing. [00:24:47] Sara Aswegan: Yeah. Yeah. [00:24:47] Lindsey Dinneen: Yeah. Oh man. Okay. Well, I could talk about this for a long time, but pivoting the conversation a little bit, just for fun. Imagine that you were to be offered a million dollars to teach masterclass on anything you want. It can be within your industry, but doesn't have to be. What would you choose to teach? [00:25:05] Sara Aswegan: Wow. That is a great question, Lindsey. A masterclass-- a million dollars-- a masterclass on anything I would want. I would be drawn to some of the advancements we're seeing in gene therapies, but I think that would be, I wanna try to serve a broader population. Do you know? I think it's, I think if I could look, I would do something around looking back on some of these, if you will use cases and best practices, to share those learnings, just because we know the impact that it will have and has had and continues to have. And not just on the scientific community, but it ripples down into the patient communities of asking that question of "what can be possible, how can we together." Instead of " no," it's actually, "yes and" or "no and" we hear something else, another construct. And really breaking it down to really enforce what I've talked about on several moments during our conversation today is it can't just be the manufacturer, the, or the developer. It can't just be academia. It can't just be health authorities or regulators. It's a collective community and it has to include that patient within that conversation to help for that learning and advancement and understanding. And so I think it's something around that, the best practices, use cases, and really things that made a difference. Meeting people where they are of a good understanding of the science, not good understanding of the science, that crosses all levels. Drug development overall. The total continuity of care for my individual affected. It's not just about a drug, but it's about assistive devices or other tools that they can have a better life. And so being really thoughtful about that I think would be something that would be really amazing. That it's actually captured and taught back. [00:26:47] Lindsey Dinneen: Yeah, absolutely. That would be a fantastic masterclass. All right, and then how do you wish to be remembered after you leave this world? [00:26:56] Sara Aswegan: Well, at some point I know my husband will admit I have the best sense of humor. [00:27:01] Lindsey Dinneen: Yes. [00:27:02] Sara Aswegan: I think for me, Lindsey, I really would hope that people would say an open heart, a generous heart, and just a connector of people, personally, professionally. It takes two seconds to be kind and open and nobody has all the answers. So help people connect with others and be willing to say, "How can I help?" [00:27:20] Lindsey Dinneen: Yeah, absolutely. Yeah. And then final question, is one thing that makes you smile every time you see or think about it? [00:27:31] Sara Aswegan: I just came in from my garden and I have to say, seeing my advancement of fostering my garden and I've got things blooming now. There is hope. [00:27:40] Lindsey Dinneen: I love that. I feel that way every time I somehow succeed in keeping a plant alive. [00:27:45] Sara Aswegan: There is hope. It's really around the simple things, right? That's it. [00:27:49] Lindsey Dinneen: Yeah, absolutely. Now, for any of our listeners who are excited to get to know about you and your work a little bit more, can you just share briefly what is it that you do right now to help companies succeed and how can people get in touch with you? [00:28:02] Sara Aswegan: Thanks, Lindsey. So I am currently doing some advisory board work for a couple of consultancies as well as helping some small and mid-sized biotechs figure out their pathway and how they go to market. How do they facilitate access to unlicensed medicines? I'm passionate about the rare space, so I'm serving also on a couple of special projects on getting drugs and diagnostics into low middle income countries. And it's something I'm very passionate about and I've got a great network of people. So if I can't help, I'm always happy to say, "Not me, however, I know someone you should talk to." And to get in touch, it's not easy to spell, but it's www.saraaswegan.com. And again, if I can't help, I might know someone who can. And I think it's just, it's really good to share our knowledge and experience and really make a difference however we can. [00:28:47] Lindsey Dinneen: Yeah. Absolutely. Well, thank you, Sara. This has been absolutely incredible to learn from you, to hear about your story. So thank you for sharing and being open. I really appreciate that. And my goodness, I just wish you the most continued success as you work change lives for a better world. [00:29:03] Sara Aswegan: Thanks Lindsey, and thanks for everything you're doing. Really, hats off. Thanks a million. [00:29:07] Lindsey Dinneen: Of course, and have the best rest of your day. And thanks also to our listeners for tuning in. If you're feeling as inspired as I am right now, I'd love it if you shared this episode with a colleague or two and we'll catch you next time. [00:29:22] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

This episode is brought to you by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Oberle Risk Strategies⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: Insurance Broker and Insurance Due Diligence Provider for Search Funds and Other Small-to-Medium-Sized Businesses⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  *This episode is brought to you by ⁠⁠⁠B⁠⁠⁠⁠⁠⁠⁠oulay, the industry standard for Quality of Earnings, tax, and audit services, serving search fund entrepreneurs for 20+ years⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠*Rob Markey is the creator of the Net Promoter Score ("NPS"), which has grown to become the de facto metric for measuring the health, loyalty and satisfaction of a customer base. He is also a longtime Partner at Bain & Company, where he founded and leads their Global Customer Strategy practice.Rob is the co-author of The Ultimate Question 2.0: How Net Promoter Companies Thrive in a Customer-Driven World, a New York Times and Wall Street Journal bestseller. Rob also teaches at Harvard Business School, and serves on several nonprofit and corporate boards, where he helps leaders build customer‑centric businesses.

What if attending a wedding, gala, or an important event didn't mean buying something new, but instead allowed you to rent a designer-quality outfit?In this episode of HappyPorch Radio we are joined by Büsra Zanner, the founder of Wearr. Wearr is a German-based startup reinventing circular fashion rental for special occasions.Büsra shares how her tech background shaped Wearr's customer-first approach, from prioritising flawless event delivery to building a data-driven platform that keeps garments in circulation longer. With a focus on convenience, automation, and strong partnerships, Wearr is proving how circular models can delight customers, extend product lifecycles, and shift mindsets away from ownership toward access.✨ In this episode:Büsra explains why customer experience must come first in rental - even before sustainability.We learn about the emotional side of circular fashion: garments creating new stories through multiple lives.Büsra talks about building a tech stack for rental that uses data to optimise sourcing, curation, and customer experience.We touch on the challenges and opportunities of sourcing: buying retail, partnering with private lenders and working with designers and retailers.We learn why focus and clarity matter for early-stage circular startups.Büsra highlights the importance of picking the right partnerships - and knowing when to say no.We find out how Wearr achieves a 100 NPS by prioritising reliability and delight.

Text us your questions and thoughts!We're excited to welcome Linda Lipovetsky, Senior Principal Customer Advocacy Manager at Unqork, whose career journey demonstrates that landing your dream role is less about polished résumés and more about delivering value, embracing radical transparency, and showing up where it counts. From a pandemic hackathon with her 10-year-old son to a gutsy LinkedIn pitch that opened the door to Unqork, Linda's story is a masterclass in building opportunity through courage and creativity.As she shares, her “operating system” is radical transparency—oversharing by design (within confidentiality) to break down silos, speed decisions, and help customers plan with the truth. No euphemisms, no carefully massaged answers—just candor that builds trust and accelerates outcomes.In this episode, we discuss:How to network into companies by creating a visible impact Self-advocacy strategies that feel naturalWhy traditional metrics like NPS and CSAT fall short (and which signals truly predict renewal and customer trust)How CS and Advocacy can claim a bigger seat at the tableThe realities of remote work, energy management, and why staying close to technology gives you long-term career liftReady to rethink how you advocate for yourself, your customers, and your career? This episode is packed with practical strategies you can start applying today—so tune in and enjoy!

In this episode, Brigitte Sager DNP discusses the importance of establishing healthy boundaries for nurse entrepreneurs. She emphasizes the need for clear communication, setting expectations with patients, and managing appointments effectively to improve patient care and prevent burnout. The conversation covers various strategies for maintaining boundaries, including cancellation policies, limiting the scope of visits, and ensuring self-care for nursing professionals.  

Too many companies see AI only as a cost-cutting shortcut, rolling out rushed AI deployments that frustrate customers. But the real opportunity lies in everyday AI: using it to handle what humans don't do well, so people can focus on what they do best—building authentic customer relationships. This week on The Modern Customer Podcast, Henrik Werdelin, founder of BARK, Prehype, Audos, and co-author of Me, My Customer, and AI, shares how everyday AI can transform CX. Highlights from the podcast: ➡️ AI Beyond Efficiency — Instead of just automating tasks, AI expands human capability and frees teams to focus on authentic customer connections. ➡️ Listening at Scale — AI makes it possible to instantly analyze thousands of customer comments, delivering insights that go far deeper than NPS scores. ➡️ Strengthening Relationship Capital — With AI, brands can build customer loyalty through three layers: depth (feeling seen), density (community), and durability (long-term trust). ➡️ Empowering Everyday Entrepreneurs — AI lowers barriers to entry, enabling more people to create businesses that solve real customer problems and build lasting relationships.

What if you could finally prove that emotions, not just price or product features, are the real drivers of revenue, retention, and revenue growth? Too many leaders know their teams create powerful emotional connections, yet they're told “emotion is a soft skill” by the very people who control the budgets. That disconnect leaves organizations stuck defending their work instead of proving its true impact. In this episode, Stacy Sherman changes that conversation. She explains why legacy metrics like CSAT and NPS fall short, and how companies like translate small emotional gestures into massive financial results. More importantly, she shares a clear framework that shows leaders exactly how to measure emotional ROI and three practical steps you can take this week. By the end, you'll see why emotion isn't a soft skill; it's the new currency of customer experience and the most strategic advantage your business has. Learn more at   Book time with Stacy Sherman through this   Listen to HBC full episode  

Among the informational signs flagged for review under the Trump administration's purge of “improper ideology” at National Parks is language at the Sitka National Monument Russian Bishop's House explaining how missionaries worked to destroy Indigenous cultures and languages in Alaska. A panel at Florida's Castillo de San Marcos National Monument is being questioned for including text about forced assimilation of imprisoned Native Americans. They are part of the ongoing review of parks, museums, and other institutions for information deemed disparaging to Americans. The review has prompted considerable concern over who is making decisions about how historical events are portrayed and whether Native historians have any input. GUESTS Michaela Pavlat (Sault Ste. Marie Tribe of Chippewa Indians), Indigenous partnerships program manager for the National Parks Conservation Association Julie Reed (Cherokee), associate professor of history at the University of Tulsa Morning Star Gali (Pit River Tribe), executive director of Indigenous Justice and the California tribal and community liaison for the International Indian Treaty Council Kimberly Smith (Eastern Band of Cherokee Indians), community conservation specialist for The Wilderness Society

Client experience is more than good service. In this episode of the PSM Show, Damion Morris and Deirdre Booth talk with Tim Amos, CPSM and Head of Growth at Client Savvy, about how AEC firms can design and manage client experiences that create measurable business results. Tim shares his journey from in-house marketing to leading CX strategy and explains why repeat business does not always equal loyalty. He introduces practical ways to measure client sentiment, including Net Promoter Score and share of spend, and describes how firms can use feedback to inform go/no-go decisions, increase profitability, and strengthen retention. For marketers, this conversation shows how CX can open the door to leadership. Small wins such as mapping the proposal process or implementing a client feedback program can build momentum and demonstrate the connection between marketing strategy and firm performance. The discussion also highlights findings from the SMPS Foundation's research on CX in the AEC industry. Listeners will gain a clear view of how intentional client experience shapes reputation, growth, and long-term success.

When Jefferey Lendrum was a boy, he loved birds. What began as a childhood passion volunteering for an ornithology program transformed into a life of wildlife crime - scaling cliffs to steal and then smuggle falcon eggs around the world. Despite multiple arrests, steep fines and various investigations - he just couldn't quit. What motivated him? How did his dedication to birds turn to destruction? This is the story of the “Pablo Escobar of Falcon Eggs”. Sources: Book - The Falcon Thief by Joshua Hammer Documentary - Poached Articles / Webpages - NPS, NPS (2), The New York Times, The Washington Post, India Times, Traffic.org For the latest NPAD updates, group travel details, merch and more, follow us on npadpodcast.com and our socials at: Instagram: @nationalparkafterdark TikTok: @nationalparkafterdark Support the show by becoming an Outsider and receive ad free listening, bonus content and more on Patreon or Apple Podcasts. Want to see our faces? Catch full episodes on our YouTube Page! Thank you to the week's partners! Soul:  For 30% off your order, head to GetSoul.com and use code NPAD. PAKA: Head to go.pakaapparel.com/NPAD and use code NPAD to grab your PAKA hoodie and free pair of alpaca crew socks Ollie: Take the online quiz and introduce Ollie to your pet. Visit https://ollie.com/npad today for 60% off your first box of meals! #ToKnowThemIsToLoveThem Liquid IV: Use our code NPAD at checkout to get 20% off your first order.

Trigger Warning: This episode discusses sexual assault and child abuse. Listener discretion is advised. In this episode of Good Nurse Bad Nurse, we welcome nurse practitioners and hosts of the Success NP podcast: Sandra and Jackie! Together with Tina, they discuss a harrowing case of medical misconduct involving Darius Paduch, a physician who abused his patients under the guise of medical necessity. The conversation delves into the psychological impact of sexual abuse, the challenges faced by victims in coming forward, and the systemic failures that allowed Paduch's actions to go unchecked for years. Later, the episode transitions to our "Good Nurse" segment featuring our guest hosts! Stay tuned as Jackie and Sandra share their journeys in the nursing field, the challenges of transitioning from nursing to nurse practitioner roles, and the importance of bridging the educational gap for new nurse practitioners. They discuss their initiative to create resources that prepare future NPs for the realities of clinical practice, emphasizing the need for practical knowledge alongside theoretical education.   To learn more about Jackie, Sandra, and their amazing podcast and resources, visit https://successnps.com/

Survey Side Hustle Showdown: Real Reviews of Sermo, ZoomRx & MoreEver wondered if those emails about “quick clinical surveys for cash” are legit? In this episode of The PA Is In, I'm diving deep into the top survey platforms for medical professionals—breaking down the pros, cons, and real earning potential of sites like Sermo, ZoomRx, MD4Lives, InCrowd, and more.This episode is your complete guide to turning survey invites into a little side income—and deciding which platforms are worth your time (and which ones to avoid).What You'll Learn:My real earnings from survey platforms like Sermo & ZoomRxWhich sites pay in cash vs. points (and what that really means)Why Sermo is more than just surveys—hello, community!Transparency around MD4Lives paymentIf Medscape ever sends actual surveysHow to stack small streams of income while you scrollLinks: SERMO: https://app.sermo.com:443/?sermoref=39d97a2c-f699-4f8b-b2f9-1eb131e18c75&utm_campaign=tell-a-friendZOOMRX: https://refer.zoomrx.com/tracyb2 Keywords: medical surveys for clinicians, side hustle for PAs, survey income for doctors, Sermo survey review, ZoomRx for healthcare providers, MD4Lives payment delay, Medscape survey payout, InCrowd review, OpinionSite survey cashout, best medical survey sites 2025, clinician side income ideas, non-clinical income for NPs, paid medical surveys, survey platforms for physician associates, how to make money answering surveys

In this high-yield episode of Curbsiders Addiction Medicine, we dive deep into a practical and compassionate approach to caring for patients using methamphetamines and/or living with methamphetamine use disorder. We explore the latest pharmacologic options, harm reduction strategies, contingency management, and innovative ideas for monitoring and supporting patients. Whether you're in primary care or other subspecialty settings, this episode is packed with pearls for every clinician with our amazing guest, Dr. Phillip Coffin, Director of the Center on Substance Use and Health in the SFDPH.  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Credits Producer/Script Writer/Show Notes: Era Kryzhanovskaya, MD Infographic and Cover Art: Zoya Surani Hosts: Carolyn Chan, MD. MHS and Era Kryzhanovskaya, MD Reviewer: Sarah Leyde MD Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Dr. Phillip Coffin Show Segments Intro, disclaimer, guest bio Guest one-liner Case from Kashlak; Definitions Four-tier approach to taking care of patients with methamphetamine use/use disorder Medications for treatment Psychosocial treatment Harm reduction New horizons in treatment  Outro Sponsor: Locumstory Learn about locums and get insights from real-life physicians, PAs and NPs at Locumstory.com Sponsor: Panacea Visit panaceafinancial.com and Panacea's Resource Library for free student loan articles, guides, and webinars built to help you make informed decisions. Sponsor: Grammarly  Download Grammarly for free at Grammarly.com/PODCAST